Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.45 +0.32 (+1.29%)
Streaming Delayed Price Updated: 1:42 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate... 
Via Benzinga
Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study. 
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Why Pfizer Stock Is Moving Higher on Thursday
Pfizer announced it will advance development of its once-daily Danuglipron. 
Via Benzinga
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Wall Street Weighs In As Pfizer Targets $100 Billion Weight Loss Market
Pfizer announced plans to advance a once-daily version of its weight loss pill, danuglipron, following encouraging early-stage trial results. 
Via Talk Markets
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Pfizer advances its once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, after positive Phase 1 pharmacokinetic study results. Dose optimization studies will follow... 
Via Benzinga
Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug
The company now plans to run multiple tests of the drug, danuglipron, to determine the right dose for registration-enabling studies. 
Via Investor's Business Daily
Premarket Stocks: 3 Fast Movers And 1 In A Buy Zone
Several stocks angled higher early Thursday with one in a buy zone and two looking to reclaim key levels. 
Via Investor's Business Daily
7 High-Yield Dividend Stocks to Buy and Hold Forever: July Edition
Explore the top seven high-yield dividend stocks, leading in several industries to buy and hold for income stability. 
Via InvestorPlace
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks. 
Via InvestorPlace
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. 
Via Benzinga
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Q2 estimates have been stable heading into earnings season, potentially setting a lower bar for corporations to beat analyst expectations and surprise to the upside. 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 No-Brainer Stocks to Buy With $100 Right Now
You don't need a mountain of cash to grow your wealth on Wall Street. 
Via The Motley Fool
Pfizer Launches Process To Identify Chief Scientific Officer Successor
Pfizer announced its starting the process to find a new chief scientific officer and president of Pfizer Research and Development. 
Via Benzinga
The 3 Most Undervalued Large-Cap Stocks to Buy in July 2024
Looking for standout picks this summer? These three undervalued large-cap stocks to buy now are compelling opportunities. 
Via InvestorPlace
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
From Pfizer Inc.
Via Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
Via Investor Brand Network
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
Via AB Newswire
Exposures COVID-19 Product Safety
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between... 
Via Benzinga
3 Overlooked Giants-in-the-Making for Patient Investors
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches. 
Via InvestorPlace
Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock
Don't ignore this drugmaker simply because it's been unable to come up with a full replacement for Lipitor. 
Via The Motley Fool
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices. 
Via The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
3 Bargain Stocks With the Potential for Mind-Boggling Returns
Discover three bargain stocks leading in healthcare and pharmaceuticals with fundamentals behind their potential for massive returns. 
Via InvestorPlace
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.